VR Logo

Biodesix Inc. (BDSX) download report

Healthcare | Diagnostics Services

Biodesix Inc. (BDSX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Please wait...

Please wait...

Please wait...

Please wait...

Please wait...

About The Company

Business: Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

IPO Date: 28-Oct-2020

Pres, CEO & Director: Mr. Scott Hutton

CFO, Sec. & Treasurer: Ms. Robin Harper Cowie


Country: United States

Headquarters: Boulder, CO

Website: https://www.biodesix.com

Key Facts

Market cap: $53.86 Mln

Revenue (TTM): $13.77 Mln

Earnings (TTM): $-51.78 Mln

Cash: $16.43 Mln

Total Debt: $12.39 Mln

Insider's Holding: 68.61%

Liquidity: Low

52 Week range: $1.25 - 14.59

Shares outstanding: 39,895,200

Stock Performance

Time Period Biodesix (BDSX) S&P BSE Sensex* S&P Small-Cap 600*
1 month-11.04-3.38-8.42
3 months-26.34-7.93-14.06
1 Year-90.350.55-17.64
3 Years--10.416.75
5 Years--11.456.18
10 Years--12.0510.23
As on 28-Jun-2022 *As on 29-Jun-2022
Year Biodesix (BDSX) S&P Small-Cap 600 S&P BSE Sensex